Greenwich LifeSciences Inc
For the period ended Dec 31, 2023. Filed Apr 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 15, 2024
GLSI$16.52+8.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
| 2023 | 2022 | |
|---|---|---|
| Revenue | $— | $— |
| Operating expenses | ||
| Research and development | 7,698,622 | 6,475,668 |
| General and administrative | 1,629,244 | 1,564,586 |
| Total operating expenses | 9,327,866 | 8,040,254 |
| Loss from operations | (9,327,866) | (8,040,254) |
| Interest income | 436,063 | 215,017 |
| Net loss | $(8,891,803) | $(7,825,237) |
| Per share information: | ||
| Net loss per common share, basic and diluted | $(0.69) | $(0.61) |
| Weighted average common shares outstanding, basic and diluted | 12,848,165 | 12,913,848 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.